BioSpace News Archive

This is the first commercial pharmaceutical agreement Aker BioMarine is entering for its new LYSOVETA business area.

Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, presented at the J.P. Morgan 39th Annual Healthcare Conference (a virtual event) in the evening of January 13, Beijing Time

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50 per share.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.